Effects of PCSK9 inhibitors on cancer, diabetes, and cardiovascular diseases

被引：0
|
作者：
Nejabat, Mojgan [1 ]
Hadizadeh, Farzin [2 ]
Almahmeed, Wael [3 ]
Sahebkar, Amirhossein [4 ,5 ]
机构：
[1] Mashhad Univ Med Sci, Sch Pharm, Dept Med Chem, Mashhad, Iran
[2] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Biotechnol Res Ctr, Mashhad, Iran
[3] Cleveland Clin Abu Dhabi, Heart & Vasc Inst, Abu Dhabi, U Arab Emirates
[4] Saveetha Univ, Saveetha Med Coll & Hosp, Saveetha Inst Med & Tech Sci, Ctr Global Hlth Res, Chennai, India
[5] Mashhad Univ Med Sci, Appl Biomed Res Ctr, Mashhad, Iran
来源：
DRUG DISCOVERY TODAY | 2025年 / 30卷 / 03期
关键词：
proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i); diabetes; cancer; cardiovascular; cerebrovascular; stroke; LDL-CHOLESTEROL; METAANALYSIS; PREVENTION; EFFICACY; THERAPY; PEOPLE; SAFETY; RISK; ERA;
D O I：
10.1016/j.drudis.2025.104316
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have potential applications in cancer therapy and as cholesterol-lowering treatments. The impact of PCSK9 suppression on both tumor growth and metastasis, as well as the management of diabetes, has been demonstrated. PCSK9i can also enhance outcomes and reduce cardiovascular (CV) events in individuals with a history of such events. In this review, we provide insights into the pharmacology, safety, and impact of PCSK9i. We highlight cutting-edge investigations, the development of innovative PCSK9i-based products, and a more comprehensive understanding of the potential effects of these drugs on cancer, diabetes, and CV and cerebrovascular diseases.
引用
收藏
页数：15
相关论文
共 50 条
  • [31] Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes
    Myers, Kelly D.
    Farboodi, Niloofar
    Mwamburi, Mkaya
    Howard, William
    Staszak, David
    Gidding, Samuel
    Baum, Seth J.
    Wilemon, Katherine
    Rader, Daniel J.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2019, 12 (08):
  • [32] PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention
    Marco-Benedi, Victoria
    Sanchez-Hernandez, Rosa M.
    Diaz, Jose Luis
    Jarauta, Estibaliz
    Suarez-Tembra, Manuel
    Pinto, Xavier
    Morillas, Carlos
    Plana, Nuria
    Pedro-Botet, Juan
    Civeira, Fernando
    LIPIDS IN HEALTH AND DISEASE, 2024, 23 (01)
  • [33] Safety of PCSK9 inhibitors
    Grzesk, Grzegorz
    Dorota, Bednarska
    Wolowiec, Lukasz
    Wolowiec, Anna
    Osiak, Joanna
    Kozakiewicz, Mariusz
    Banach, Joanna
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 156
  • [34] Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease
    Wojcik, Cezary
    POSTGRADUATE MEDICINE, 2017, 129 (08) : 801 - 810
  • [35] PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
    Jia, Xiaoming
    Al Rifai, Mahmoud
    Saeed, Anum
    Ballantyne, Christie M.
    Virani, Salim S.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2022, 18 : 555 - 566
  • [36] Access to PCSK9 Inhibitors
    Baum, Seth J.
    Lepor, Norman E.
    Robinson, Jennifer G.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2018, 19 : S47 - S50
  • [37] Oral PCSK9 Inhibitors
    Anandita Agarwala
    Ramsha Asim
    Christie M. Ballantyne
    Current Atherosclerosis Reports, 2024, 26 : 147 - 152
  • [38] PCSK9 inhibitors are go
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (09) : 593 - 593
  • [39] Oral PCSK9 Inhibitors
    Agarwala, Anandita
    Asim, Ramsha
    Ballantyne, Christie M.
    CURRENT ATHEROSCLEROSIS REPORTS, 2024, 26 (05) : 147 - 152
  • [40] PCSK9 inhibitors are go
    Asher Mullard
    Nature Reviews Drug Discovery, 2015, 14 : 593 - 593
12345